These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hypercalcemia of malignancy: a review of advances in pathophysiology. Kaplan M Oncol Nurs Forum; 1994 Jul; 21(6):1039-46; quiz 1047-8. PubMed ID: 7971410 [TBL] [Abstract][Full Text] [Related]
4. [Calcium homeostasis and orientational considerations in evaluation and therapy of hypercalcemic syndromes]. Nurra P Arch Sci Med (Torino); 1981; 138(4):455-8. PubMed ID: 7340730 [No Abstract] [Full Text] [Related]
5. [Metabolic bone diseases: malignancy-associated hypercalcemia]. Hamada M; Takeda R Nihon Rinsho; 1986 Nov; 44(11):2467-72. PubMed ID: 3546802 [No Abstract] [Full Text] [Related]
6. Cancer-related hypercalcemia: how to spot it, how to manage it. Clayton K Am J Nurs; 1997 May; 97(5):42-8; quiz 49. PubMed ID: 9155796 [No Abstract] [Full Text] [Related]
7. Cancer-related hypercalcemia. Seccareccia D Can Fam Physician; 2010 Mar; 56(3):244-6, e90-2. PubMed ID: 20228307 [No Abstract] [Full Text] [Related]
8. Hypercalcemia of cancer: an update. Goni MH; Tolis G Anticancer Res; 1993; 13(4):1155-60. PubMed ID: 8352538 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in pathophysiology and treatment of hypercalcemia of malignancy. Mundy GR; Yates AJ Am J Kidney Dis; 1989 Jul; 14(1):2-12. PubMed ID: 2662763 [No Abstract] [Full Text] [Related]
10. Tumor products and the hypercalcemia of malignancy. Mundy GR Rev Med Brux; 1987; 8(6-7):353-7. PubMed ID: 3671927 [No Abstract] [Full Text] [Related]
12. Mediators of bone resorption and hypercalcemia in cancer. Pugliese G N Engl J Med; 1988 Mar; 318(10):642-3. PubMed ID: 3344013 [No Abstract] [Full Text] [Related]
13. Hypercalcemia in malignant disease. Hanagan JR Clin Ther; 1982; 5(2):102-12. PubMed ID: 6760966 [TBL] [Abstract][Full Text] [Related]
14. [Extraparathyroid hypercalcemias. Physiopathological and therapeutic aspects]. Houillier P; Blanchard A; Paillard M Ann Med Interne (Paris); 1997; 148(1):15-8. PubMed ID: 9137694 [TBL] [Abstract][Full Text] [Related]
16. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357 [TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449 [TBL] [Abstract][Full Text] [Related]
20. Hypercalcaemia due to malignancy. Role of the kidney and treatment. Sleeboom HP; Bijvoet OL Contrib Nephrol; 1982; 33():178-96. PubMed ID: 6214375 [No Abstract] [Full Text] [Related] [Next] [New Search]